URMC Research Network - Jonathan Friedberg

Find People

Jonathan Friedberg

Title	Professor
Institution	School of Medicine and Dentistry
Department	Medicine
Address	University of Rochester Medical Center School of Medicine and Dentistry 601 Elmwood Ave, Box 704 Rochester NY 14642

Other Positions


Title	Acting Director
Institution	University of Rochester Medical Center
Department	Cancer Center
Title	Chief
Institution	School of Medicine and Dentistry
Department	Medicine
Division	Medicine - Hematology/Oncology

Title	Professor
Institution	University of Rochester Medical Center
Department	Cancer Center

Awards And Honors

2001	-	2003	Clinical Oncology Research Fellowship " Immunotherapy of Hodgkin's Disease" \| Berlex Oncology Foundation
2001	-	2003	Rising stars program for innovative research \| Dunkin Donuts and Dana-Farber Cancer Institute Department of Adu
2003			Clinical Investigator Career Development Award \| Lymphoma Research Foundation
2004	-	2006	Lawrence A. Kohn Senior Teaching Fellow \| Institute of Medicine
2007			Jacob Gitleman Award \| Gilda's Club and Cancer Action
2008			Scholar in Clinical Research \| Leukemia and Lymphoma Society
2008			America's Top Doctors Selection
2012			Faculty Academic Mentoring Award \| University of Rochester School of Medicine and Dentistry

Overview

Jonathan W. Friedberg, M.D., is Director of the James P. Wilmot Cancer Center, Chief of Hematology/Oncology and Director of Hematological Malignancies Clinical Research.

He is a driving force behind the operations of our clinical programs and a key member of the center's lymphoma Specialized Program of Research Excellence, funded by the National Cancer Institute.

Friedberg is a member of the lymphoma committee in the Southwest Oncology Group, and serves as principal investigator on many local and national lymphoma treatment protocols for both Hodgkin lymphoma and non-Hodgkin's lymphoma.

Dr. Friedberg received his medical degree from Harvard Medical School. His postgraduate training included an internship and residency at Massachusetts General Hospital. He also completed a medical oncology and hematology fellowship at Dana-Farber/Partners Cancer Care in Boston. Dr. Friedberg also has an M.M.Sc. degree from Harvard Medical School in clinical investigation. He holds subspecialty certification in Medical Oncology and Hematology.

His research interests focus on development of novel therapies for patients with lymphoma. Most recently, he was awarded the Scholar in Clinical Research award from the Leukemia & Lymphoma Society, based upon his work with an oral inhibitor of a protein called Syk, which demonstrated efficacy in the treatment of several different forms of lymphoma, and was selected as a plenary presentation at the annual meeting of the American Society of Hematology.

Selected Publications

Press OW, Unger JM, Rimsza LM, Friedberg JW, Leblanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. J Clin Oncol. 2013 Jan 20; 31(3):314-20.

View in: PubMed
Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. 2013 Feb; 24(2):441-8.

View in: PubMed
Friedberg JW. Double-hit diffuse large B-cell lymphoma. J Clin Oncol. 2012 Oct 1; 30(28):3439-43.

View in: PubMed
Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, Cerhan JR, Zelenetz AD, Hirata J, Miller TP. Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study. J Clin Oncol. 2012 Sep 20; 30(27):3368-75.

View in: PubMed
Friedberg JW. Mantle cell lymphoma. Best Pract Res Clin Haematol. 2012 Jun; 25(2):131-2.

View in: PubMed
Noel MS, Friedberg JW, Barr PM. Novel agents in mantle cell lymphoma. Best Pract Res Clin Haematol. 2012 Jun; 25(2):191-200.

View in: PubMed
Nabhan C, Byrtek M, Taylor MD, Friedberg JW, Cerhan JR, Hainsworth JD, Miller TP, Hirata J, Link BK, Flowers CR. Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: Report from the National LymphoCare Study. Cancer. 2012 Oct 1; 118(19):4842-50.

View in: PubMed
Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S. Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo. Mol Cancer Ther. 2012 May; 11(5):1122-32.

View in: PubMed
Biswas T, Culakova E, Friedberg JW, Kelly JL, Dhakal S, Liesveld J, Phillips GL, Constine LS. Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. Radiother Oncol. 2012 Jun; 103(3):367-72.

View in: PubMed
Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Lacasce AS. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma. 2012 Jun; 53(6):1113-6.

View in: PubMed
LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012 Mar 1; 119(9):2093-9.

View in: PubMed
Barr PM, Wei C, Roger J, Schaefer-Cutillo J, Kelly JL, Rosenberg AF, Jung J, Sanz I, Friedberg JW. Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. Clin Immunol. 2012 Mar; 142(3):237-42.

View in: PubMed
Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M, Milner L, Phillips G, Friedberg JW. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma. 2012 May; 53(5):830-5.

View in: PubMed
Kumar A, Vanderplas A, Lacasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Findings from a large national database. Cancer. 2012 Jun 1; 118(11):2944-51.

View in: PubMed
Keller SF, Kelly JL, Sensenig E, Andreozzi J, Oliva J, Rich L, Constine L, Becker M, Phillips G, Liesveld J, Fisher RI, Bernstein SH, Friedberg JW. Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin's Lymphoma (HL) in the ABVD Therapeutic Era. Biol Blood Marrow Transplant. 2012 Apr; 18(4):640-7.

View in: PubMed
Friedberg JW. New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clin Cancer Res. 2011 Oct 1; 17(19):6112-7.

View in: PubMed
Carter SJ, Bernstein SH, Friedberg JW, Barr PM. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res. 2011 Nov; 35(11):e223-4.

View in: PubMed
Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011 Sep; 10(9):1686-97.

View in: PubMed
Milner LA, Becker MW, Bernstein SH, Bruckner L, Friedberg JW, Holland GA, Ifthikharuddin JJ, Liesveld JL, Mathes EJ, Menchel HL, Mullen CA, Sasson T, Phillips GL. Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. Am J Hematol. 2011 Aug; 86(8):712-4.

View in: PubMed
Barr PM, Friedberg JW. Getting to the heart of the problem in treating diffuse large B-cell lymphoma. Leuk Lymphoma. 2011 Jul; 52(7):1166-7.

View in: PubMed
Friedberg JW. Hodgkin lymphoma: answers take time! Blood. 2011 May 19; 117(20):5274-6.

View in: PubMed
Das P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II. J Am Coll Radiol. 2011 May; 8(5):302-8.

View in: PubMed
Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011 Mar 10; 117(10):2807-12.

View in: PubMed
Friedberg JW. CLL microenvironment: macro important. Blood. 2011 Jan 13; 117(2):377-8.

View in: PubMed
Friedberg JW. Relapsed/Refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011; 2011:498-505.

View in: PubMed
Friedberg JW. Rituximab maintenance in follicular lymphoma: PRIMA. Lancet. 2011 Jan 1; 377(9759):4-6.

View in: PubMed
Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):452-7.

View in: PubMed
Phillips GL, Bernstein SH, Liesveld JL, Abboud CN, Becker MW, Constine LS, Ifthikharuddin JJ, Loughner JE, Milner LA, Vesole DH, Friedberg JW. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1033-42.

View in: PubMed
Czuczman M, Straus D, Gribben J, Bredenfeld H, Friedberg J, Bollard C. Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas. Leuk Lymphoma. 2010 Aug; 51 Suppl 1:41-9.

View in: PubMed
Dougherty DW, Friedberg JW. Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy? Curr Hematol Malig Rep. 2010 Jul; 5(3):148-56.

View in: PubMed
Burack WR, Laughlin TS, Friedberg JW, Spence JM, Rothberg PG. PCR assays detect B-lymphocyte clonality in formalin-fixed, paraffin-embedded specimens of classical hodgkin lymphoma without microdissection. Am J Clin Pathol. 2010 Jul; 134(1):104-11.

View in: PubMed
Ng A, Constine LS, Advani R, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. Curr Probl Cancer. 2010 May-Jun; 34(3):211-27.

View in: PubMed
Kahl BS, Cheson BD, Friedberg JW. Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Clin Adv Hematol Oncol. 2010 May; 8(5):1-16.

View in: PubMed
Kelly JL, Friedberg JW, Calvi LM, van Wijngaarden E, Fisher SG. A case-control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults. Cancer Causes Control. 2010 Aug; 21(8):1265-75.

View in: PubMed
Sousou T, Friedberg J. Rituximab in indolent lymphomas. Semin Hematol. 2010 Apr; 47(2):133-42.

View in: PubMed
Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 2010 Jun 3; 115(22):4478-87.

View in: PubMed
Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk. 2010 Feb; 10(1):21-7.

View in: PubMed
Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P, Grant S. Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leuk Res. 2010 Mar; 34(3):379-86.

View in: PubMed
Friedberg JW. PET positive, PET negative, or PET peeve? Blood. 2010 Jan 28; 115(4):752-3.

View in: PubMed
Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 1; 115(13):2578-85.

View in: PubMed
Kelly JL, Friedberg JW, Calvi LM, van Wijngaarden E, Fisher SG. Vitamin D and non-Hodgkin lymphoma risk in adults: a review. Cancer Invest. 2009 Nov; 27(9):942-51.

View in: PubMed
Ban-Hoefen M, Bernstein SH, Bisognano JD, Pryor JG, Friedberg JW. Symptomatic intracardiac diffuse large B-cell lymphoma. Am J Hematol. 2009 Oct; 84(10):683-5.

View in: PubMed
Friedberg JW. Bendamustine in chronic lymphocytic leukemia: the future is combination therapy. Leuk Lymphoma. 2009 Sep; 50(9):1399-400.

View in: PubMed
Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys. 2010 May 1; 77(1):79-85.

View in: PubMed
Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma. 2009 Aug; 9(4):307-10.

View in: PubMed
Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 Aug; 146(3):282-91.

View in: PubMed
Sud R, Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma: on the threshold of new therapies. Oncology (Williston Park). 2009 Jun; 23(7):615-6, 619.

View in: PubMed
Dasmahapatra G, Lembersky D, Rahmani M, Kramer L, Friedberg J, Fisher RI, Dent P, Grant S. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther. 2009 May; 8(9):808-19.

View in: PubMed
Mendler JH, Friedberg JW. Salvage therapy in Hodgkin's lymphoma. Oncologist. 2009 Apr; 14(4):425-32.

View in: PubMed
Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, Joyce R, Takvorian RW, Fisher DC, Fisher RI, Liesveld J, Marquis D, Neuberg D, Freedman AS. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009 Jun; 145(6):741-8.

View in: PubMed
Friedberg JW. The emerging role of bendamustine in follicular lymphoma. Leuk Lymphoma. 2009 Mar; 50(3):317-8.

View in: PubMed
Dhakal S, Biswas T, Liesveld JL, Friedberg JW, Phillips GL, Constine LS. Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2009 Sep 1; 75(1):188-92.

View in: PubMed
Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, Rogers ES, Hainsworth JD, Wong EK, Vose JM, Zelenetz AD, Link BK. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009 Mar 10; 27(8):1202-8.

View in: PubMed
Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ, Bankert RB, Bernstein SH. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood. 2009 Apr 16; 113(16):3809-12.

View in: PubMed
McLaughlin P, Friedberg JW. Seeking wisdom from the Seer. Leuk Lymphoma. 2009 Feb; 50(2):145-7.

View in: PubMed
Sud R, Friedberg JW. Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab. Haematologica. 2008 Dec; 93(12):1776-80.

View in: PubMed
Kho ME, Lepisto EM, Niland JC, Friedberg JW, Lacasce AS, Weeks JC. Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database. Cancer. 2008 Dec 1; 113(11):3209-12.

View in: PubMed
Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol. 2009 Jan 1; 27(1):114-9.

View in: PubMed
Sikder MA, Friedberg JW. Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Hematol Malig Rep. 2008 Oct; 3(4):187-93.

View in: PubMed
Friedberg JW, Fisher RI. Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2008 Oct; 22(5):941-52, ix.

View in: PubMed
LaCasce AS, Kho ME, Friedberg JW, Niland JC, Abel GA, Rodriguez MA, Czuczman MS, Millenson MM, Zelenetz AD, Weeks JC. Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol. 2008 Nov 1; 26(31):5107-12.

View in: PubMed
Sikder MA, Friedberg JW. Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Oncol Rep. 2008 Sep; 10(5):420-6.

View in: PubMed
Friedberg JW. Treatment of follicular non-Hodgkin's lymphoma: the old and the new. Semin Hematol. 2008 Jul; 45(3 Suppl 2):S2-6.

View in: PubMed
Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec; 32(12):1830-6.

View in: PubMed
Friedberg JW. Bak to death with chemotherapy. Blood. 2008 Jun 1; 111(11):5263-4.

View in: PubMed
Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol. 2008 Oct; 19(10):1759-64.

View in: PubMed
Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J, Friedberg JW. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest. 2008 May; 26(4):431-3.

View in: PubMed
Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A. Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma. 2008 May; 49(5):902-9.

View in: PubMed
Link BK, Friedberg JW. Monoclonal antibodies in lymphoma: the first decade. Semin Hematol. 2008 Apr; 45(2):71-4.

View in: PubMed
Schaefer-Cutillo J, Friedberg JW. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma. Semin Hematol. 2008 Apr; 45(2):110-7.

View in: PubMed
Friedberg JW. Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma. Haematologica. 2008 Mar; 93(3):336-8.

View in: PubMed
Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008 Jan 10; 26(2):204-10.

View in: PubMed
Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program. 2008; 341-8.

View in: PubMed
Barr P, Fisher R, Friedberg J. The role of bortezomib in the treatment of lymphoma. Cancer Invest. 2007 Dec; 25(8):766-75.

View in: PubMed
Leonard JP, Friedberg JW, Hagemeister FB, Levine AM. Combination treatment approaches and novel therapies for lymphoma. Clin Adv Hematol Oncol. 2007 Aug; 5(8 Suppl 12):4-20; quiz 1 p following 20.

View in: PubMed
Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol. 2007 Jul; 18(7):1216-23.

View in: PubMed
Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007 Jun; 18(6):1071-9.

View in: PubMed
Schaefer-Cutillo J, Friedberg JW, Fisher RI. Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. Oncology (Williston Park). 2007 Feb; 21(2):203-12; discussion 214, 217, 221.

View in: PubMed
Friedberg JW. Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma. Haematologica. 2006 Nov; 91(11):1453-5.

View in: PubMed
Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, Kelly J, Milner EC, Fisher RI, Sanz I. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2007 Feb; 122(2):139-45.

View in: PubMed
Friedberg JW, Freedman AS. Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma. Curr Treat Options Oncol. 2006 Jul; 7(4):276-84.

View in: PubMed
Friedberg JW. Rituximab for early-stage diffuse large-B-cell lymphoma. Lancet Oncol. 2006 May; 7(5):357-9.

View in: PubMed
Friedberg JW, Fisher RI. Diffuse large B-cell NHL. Cancer Treat Res. 2006; 131:121-40.

View in: PubMed
Vargas RL, Fallone E, Felgar RE, Friedberg JW, Arbini AA, Andersen AA, Rothberg PG. Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience. Leuk Res. 2006 May; 30(5):547-51.

View in: PubMed
Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005 Apr 1; 23(10):2208-14.

View in: PubMed
Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program. 2005; 329-34.

View in: PubMed
Phillips GL, Abboud CN, Bernstein SH, Friedberg JW, Ifthikharuddin JJ, Lancet JE, Liesveld JL, Spreng E, Johnson V, Chapman M, Vesole DH. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report. Semin Oncol. 2004 Dec; 31(6 Suppl 18):59-61.

View in: PubMed
Friedberg JW. Radioimmunotherapy for non-Hodgkin's lymphoma. Clin Cancer Res. 2004 Dec 1; 10(23):7789-91.

View in: PubMed
Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004 Nov 1; 22(21):4302-11.

View in: PubMed
Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood. 2005 Jan 15; 105(2):489-95.

View in: PubMed
Friedberg JW. Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era. Clin Cancer Res. 2004 Aug 15; 10(16):5297-8.

View in: PubMed
Friedberg JW, Fisher RI. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2004 Feb; 4(1):18-26.

View in: PubMed
Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC, Gribben JG, Kim H, Nadler LM, Freedman AS. Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma. 2004 Feb; 45(2):315-20.

View in: PubMed
Friedberg JW, Dong DA, Li S, Kim H, Stephans K, Noonan K, Neuberg D, Gribben JG, Fisher DC, Freedman AS, Takvorian T, Jurgens R, Battle TE, Frank DA. Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. Leuk Res. 2004 Feb; 28(2):139-47.

View in: PubMed
Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004 Jan; 45(1):85-92.

View in: PubMed
Friedberg JW, Kim H, Li S, Neuberg D, Boyd K, Daley H, Fisher DC, Gribben JG, Spitzer T, Freedman AS. Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003 Oct; 32(7):681-6.

View in: PubMed
Friedberg JW, Neuberg D, Kim H, Miyata S, McCauley M, Fisher DC, Takvorian T, Canellos GP. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer. 2003 Sep 1; 98(5):978-82.

View in: PubMed
Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: current status. Oncologist. 2003; 8(5):438-47.

View in: PubMed
Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002 Sep 15; 100(6):1989-96.

View in: PubMed
Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM, Daley J, Soiffer R, Ritz J, Freedman AS. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol. 2002 Jun; 117(4):828-34.

View in: PubMed
Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002 Apr 15; 20(8):2101-8.

View in: PubMed
Gaudet G, Friedberg JW, Weng A, Pinkus GS, Freedman AS. Breast lymphoma associated with breast implants: two case-reports and a review of the literature. Leuk Lymphoma. 2002 Jan; 43(1):115-9.

View in: PubMed
Webb IJ, Friedberg W, Gribben JG, Fisher DC, Spitzer T, Neuberg D, Jallow H, Kim H, Houde H, Monroy R, Schmittling R, Freedman AS. Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2002; 8(8):429-34.

View in: PubMed
Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, Soiffer RJ. Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(11):601-7.

View in: PubMed
Hahn SM, Smith RP, Friedberg J. Photodynamic therapy for mesothelioma. Curr Treat Options Oncol. 2001 Oct; 2(5):375-83.

View in: PubMed
Coyte PC, Croxford R, McIsaac W, Feldman W, Friedberg J. The role of adjuvant adenoidectomy and tonsillectomy in the outcome of the insertion of tympanostomy tubes. N Engl J Med. 2001 Apr 19; 344(16):1188-95.

View in: PubMed
Friedberg JW, Neuberg D, Monson E, Jallow H, Nadler LM, Freedman AS. The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2001; 7(8):446-53.

View in: PubMed
Freedman A, Friedberg JW, Gribben J. High-dose therapy for follicular lymphoma. Oncology (Williston Park). 2000 Mar; 14(3):321-6, 329; discussion 330-2, 338.

View in: PubMed
Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999 Oct 15; 86(8):1621-7.

View in: PubMed
Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999 Oct; 17(10):3128-35.

View in: PubMed
Friedberg JW, Freedman AS. High-dose therapy and stem cell transplantation in follicular lymphoma. Ann Hematol. 1999 May; 78(5):203-11.

View in: PubMed
Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ, Takvorian T, Fisher DC, Schlossman R, Jallow H, Kuhlman C, Ritz J, Freedman AS. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant. 1999; 5(4):262-8.

View in: PubMed
Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry. 1998 Mar-Apr; 5(6):293-306.

View in: PubMed
Friedberg JW, Frankenburg FR, Burk J, Johnson W. Clozapine-caused eosinophilic colitis. Ann Clin Psychiatry. 1995 Jun; 7(2):97-8.

View in: PubMed
Hui Y, Friedberg J, Crysdale WS. Congenital nasal pyriform aperture stenosis as a presenting feature of holoprosencephaly. Int J Pediatr Otorhinolaryngol. 1995 Mar; 31(2-3):263-74.

View in: PubMed
Papsin BC, Friedberg J. Aerodigestive-tract foreign bodies in children: pitfalls in management. J Otolaryngol. 1994 Apr; 23(2):102-8.

View in: PubMed
Banov MD, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry. 1993 Dec; 54(12):466-9.

View in: PubMed
Mounsey RA, Forte V, Friedberg J. First brachial cleft sinuses: an analysis of current management strategies and treatment outcomes. J Otolaryngol. 1993 Dec; 22(6):457-61.

View in: PubMed
Friedberg JW. From municipal hospital to medical center: Milwaukee County General Hospital, 1965-1980. Wis Med J. 1992 Sep; 91(9):547-9.

View in: PubMed
Noyek AM, Friedberg J. Thyroglossal duct and ectopic thyroid disorders. Otolaryngol Clin North Am. 1981 Feb; 14(1):187-201.

View in: PubMed